These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 3026625)

  • 1. Phase I and pharmacokinetic study of trans-N3P3Az2(NHMe)4.
    Mulder NH; Meijers WH; van der Meulen JD; Sleijfer DT; Uges DR; de Vries EG; Postmus PE; van de Grampel JC; Willemse PH
    Cancer Treat Rep; 1987 Feb; 71(2):155-9. PubMed ID: 3026625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II evaluation of trans-N3P3Az2(NHMe)4 (AZP) in non-small cell lung cancer.
    Postmus PE; Mulder NH; Grampel JC; Meyers WH; Berendsen HH
    Eur J Cancer Clin Oncol; 1987 Aug; 23(8):1207-8. PubMed ID: 2820748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and clinical pharmacologic studies of aziridinylbenzoquinone.
    Griffin JP; Newman RA; McCormack JJ; Krakoff IH
    Cancer Treat Rep; 1982 Jun; 66(6):1321-5. PubMed ID: 7083235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of diaziquone.
    Frytak S; Eagan RT; Ames MM; Creagan ET; Nichols WC
    Cancer Treat Rep; 1984; 68(7-8):975-8. PubMed ID: 6744349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of diaziquone in patients with advanced carcinoma of the lung.
    Frytak S; Eagan RT; Creagan ET; Nichols WC
    Cancer Treat Rep; 1984 Sep; 68(9):1193-4. PubMed ID: 6478455
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase I evaluation and pharmacokinetics of aziridinylbenzoquinone using a weekly intravenous schedule.
    Schilcher RB; Young JD; Leichman LP; Haas CD; Baker LH
    Cancer Res; 1983 Aug; 43(8):3907-11. PubMed ID: 6683127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of a five-day dose schedule of 4-Ipomeanol in patients with non-small cell lung cancer.
    Kasturi VK; Dearing MP; Piscitelli SC; Russell EK; Sladek GG; O'Neil K; Turner GA; Morton TL; Christian MC; Johnson BE; Kelley MJ
    Clin Cancer Res; 1998 Sep; 4(9):2095-102. PubMed ID: 9748125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial and pharmacokinetics of aziridinylbenzoquinone (NSC 182986) in humans.
    Schilsky RL; Kelley JA; Ihde DC; Howser DM; Cordes RS; Young RC
    Cancer Res; 1982 Apr; 42(4):1582-6. PubMed ID: 7060028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
    Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of diaziquone in advanced soft tissue and bony sarcoma: a Southwest Oncology Group study.
    Zidar BL; Baker LH; Rivkin SE; Balcerzak SP; Stephens RL
    Cancer Treat Rep; 1985 Sep; 69(9):1035-6. PubMed ID: 4028037
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase II clinical evaluation of AZQ in metastatic breast cancer.
    Yap HY; Bedikian AY; Schell FC; Blumenschein GR; Bodey GP
    Am J Clin Oncol; 1983 Feb; 6(1):31-3. PubMed ID: 6837505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer.
    Tan CT; Hancock CH; Mondora A; Hoffman NW
    Cancer Res; 1984 Feb; 44(2):831-5. PubMed ID: 6692381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
    Chen HX; Marshall JL; Ness E; Martin RR; Dvorchik B; Rizvi N; Marquis J; McKinlay M; Dahut W; Hawkins MJ
    Clin Cancer Res; 2000 Apr; 6(4):1259-66. PubMed ID: 10778949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of diaziquone in advanced upper aerodigestive cancer.
    Creagan ET; Long HJ; Kvols LK; Edmonson JH; O'Fallon JR
    Cancer Treat Rep; 1985 Jan; 69(1):141. PubMed ID: 3967258
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II clinical trial of diaziquone in bronchogenic carcinoma.
    Chiuten DF; Umsawasdi T; Dhingra HM; Murphy WK; Spitzer G; Carr DT; Bodey GP; Valdivieso M
    Cancer Treat Rep; 1985; 69(7-8):921-2. PubMed ID: 4016800
    [No Abstract]   [Full Text] [Related]  

  • 16. A phase I/II trial of combination paclitaxel and carboplatin in advanced or metastatic non-small cell lung cancer: preliminary results of an ongoing study.
    Natale RB
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):34-7. PubMed ID: 8643968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer.
    Horti J; Juhasz E; Monostori Z; Maeda K; Eckhardt S; Bodrogi I
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):173-80. PubMed ID: 18214483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.
    Faivre S; Raymond E; Boige V; Gatineau M; Buthaut X; Rixe O; Bernareggi A; Camboni G; Armand JP
    Clin Cancer Res; 2001 Jan; 7(1):43-50. PubMed ID: 11205916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of diaziquone in patients with colon cancer.
    Neidhart JA; Erlichman C; Robert F; Velez-Garcia E; Bender JF; Grillo-López J
    Cancer Treat Rep; 1985 Feb; 69(2):215-7. PubMed ID: 3882229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy.
    Huisman C; Biesma B; Postmus PE; Giaccone G; Schramel FM; Smit EF
    Br J Cancer; 2001 Nov; 85(10):1456-61. PubMed ID: 11720428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.